Personal tools

DOID:14566

From FANTOM5_SSTAR

Jump to: navigation, search

Name:disease of cellular proliferation
Namespace:FANTOM
Definition:"A disease that is characterized by abnormally rapid cell division." [url:http://en.wikipedia.org/w/index.php?title
Synonyms: "cell process disease" EXACT []
Alt_id: DOID:0000818

Ontology association
Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.

link to ontology dataset
data

Parents

is_a:DOID:4(disease)



Children


is a:DOID:0060072 (benign neoplasm),DOID:162 (cancer)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:14566 (disease of cellular proliferation), sorted by p-values
Analyst: Hideya Kawaji

link to source dataset
human : data
mouse : data

P-valueFFCPShort description
1.11e-77FFCP PHASE1:Hg19::chrX:153991088..153991168,+#_a069a9edb8a377d70919f7a15e49ddd6p1@DKC1
1.11e-77FFCP PHASE2:Hg19::chrX:153991088..153991168,+#_a069a9edb8a377d70919f7a15e49ddd6p1@DKC1
4.12e-73FFCP PHASE1:Hg19::chr11:1372935..1372952,+#_4e81f74e33f1aed7a98394b0daae6044p@chr11:1372935..1372952, +
4.12e-73FFCP PHASE2:Hg19::chr11:1372935..1372952,+#_4e81f74e33f1aed7a98394b0daae6044p@chr11:1372935..1372952, +
7.94e-66FFCP PHASE2:Hg19::chr2:197504410..197504471,+#_6e45ddc3676cc3452476b3211bc5749cp1@CCDC150
7.94e-66FFCP PHASE1:Hg19::chr2:197504410..197504471,+#_6e45ddc3676cc3452476b3211bc5749cp1@CCDC150
8.26e-65FFCP PHASE2:Hg19::chr17:38444115..38444194,+#_164d2f7f2cb166c50db4781f26756a77p1@CDC6
8.26e-65FFCP PHASE1:Hg19::chr17:38444115..38444194,+#_164d2f7f2cb166c50db4781f26756a77p1@CDC6
2.36e-64FFCP PHASE1:Hg19::chr17:41277372..41277418,-#_841fd575e01a3b52e3c3a67dc1d89cb5p1@BRCA1
2.36e-64FFCP PHASE2:Hg19::chr17:41277372..41277418,-#_841fd575e01a3b52e3c3a67dc1d89cb5p1@BRCA1
6.38e-64FFCP PHASE1:Hg19::chrX:153991175..153991226,+#_1cb476246f8db081b6c140351fb1eb4ep2@DKC1
6.38e-64FFCP PHASE2:Hg19::chrX:153991175..153991226,+#_1cb476246f8db081b6c140351fb1eb4ep2@DKC1
1.3e-63FFCP PHASE1:Hg19::chr20:57617831..57617909,-#_64b7f815413b36a8c409d99bd10de946p1@SLMO2
1.3e-63FFCP PHASE2:Hg19::chr20:57617831..57617909,-#_64b7f815413b36a8c409d99bd10de946p1@SLMO2
3.85e-63FFCP PHASE2:Hg19::chr1:214776516..214776565,+#_82e117f810e745ec6abfcf1dc89e4491p1@CENPF
3.85e-63FFCP PHASE1:Hg19::chr1:214776516..214776565,+#_82e117f810e745ec6abfcf1dc89e4491p1@CENPF
7.33e-63FFCP PHASE2:Hg19::chr2:198364552..198364576,-#_11ecfa860f54fd992c18a89591fa6276p1@HSPD1
7.33e-63FFCP PHASE1:Hg19::chr2:198364552..198364576,-#_11ecfa860f54fd992c18a89591fa6276p1@HSPD1
1.04e-62FFCP PHASE2:Hg19::chr7:56119449..56119492,+#_8772def32e6ef50ea8c4d9289cb9796dp1@CCT6A
1.04e-62FFCP PHASE1:Hg19::chr7:56119449..56119492,+#_8772def32e6ef50ea8c4d9289cb9796dp1@CCT6A
1.45e-62FFCP PHASE2:Hg19::chr8:124408630..124408647,-#_3f613050903461e86c69f38ea5321b68p2@ATAD2
1.45e-62FFCP PHASE1:Hg19::chr8:124408630..124408647,-#_3f613050903461e86c69f38ea5321b68p2@ATAD2
1.65e-62FFCP PHASE1:Hg19::chr1:154947126..154947147,+#_8848bd404d49272423441104d0ba3334p2@CKS1B
1.65e-62FFCP PHASE2:Hg19::chr1:154947126..154947147,+#_8848bd404d49272423441104d0ba3334p2@CKS1B
4.1e-62FFCP PHASE2:Hg19::chr1:214776570..214776593,+#_4ce1635fbc63873a924f428eb99a590cp2@CENPF
4.1e-62FFCP PHASE1:Hg19::chr1:214776570..214776593,+#_4ce1635fbc63873a924f428eb99a590cp2@CENPF
7.02e-62FFCP PHASE1:Hg19::chr3:179280702..179280769,+#_92f5450b66a179bf72e794994773f4fcp1@ACTL6A
7.02e-62FFCP PHASE2:Hg19::chr3:179280702..179280769,+#_92f5450b66a179bf72e794994773f4fcp1@ACTL6A
7.23e-62FFCP PHASE2:Hg19::chr1:154947148..154947175,+#_a8180e5af452ae44a4e6215ac1e22d39p1@CKS1B
7.23e-62FFCP PHASE1:Hg19::chr1:154947148..154947175,+#_a8180e5af452ae44a4e6215ac1e22d39p1@CKS1B
1.53e-61FFCP PHASE2:Hg19::chr4:57301645..57301675,-#_d5d9b8ed7dfc2143c3597c887420eda2p2@PPAT
1.53e-61FFCP PHASE1:Hg19::chr4:57301645..57301675,-#_d5d9b8ed7dfc2143c3597c887420eda2p2@PPAT
1.96e-61FFCP PHASE2:Hg19::chr7:105162652..105162709,-#_86ff9cdddf579e246fad466840dad718p1@PUS7
1.96e-61FFCP PHASE1:Hg19::chr7:105162652..105162709,-#_86ff9cdddf579e246fad466840dad718p1@PUS7
3.33e-61FFCP PHASE1:Hg19::chr17:38574169..38574180,-#_14e3b1825f5fd31470f4dd9e483d5affp2@TOP2A
3.33e-61FFCP PHASE2:Hg19::chr17:38574169..38574180,-#_14e3b1825f5fd31470f4dd9e483d5affp2@TOP2A
4.29e-61FFCP PHASE1:Hg19::chr1:211848955..211848981,-#_55ebf954411c5e3590431e6c5718d42ep1@NEK2
4.29e-61FFCP PHASE2:Hg19::chr1:211848955..211848981,-#_55ebf954411c5e3590431e6c5718d42ep1@NEK2
5.28e-61FFCP PHASE1:Hg19::chr11:125495862..125495882,+#_6db2b8a81d2606d8d1c7eb18db656dd9p1@CHEK1
5.28e-61FFCP PHASE2:Hg19::chr11:125495862..125495882,+#_6db2b8a81d2606d8d1c7eb18db656dd9p1@CHEK1
7.39e-61FFCP PHASE2:Hg19::chr3:172468505..172468582,+#_0a51a991cdcb04b9213caaba2b7b72fcp1@ECT2
7.39e-61FFCP PHASE1:Hg19::chr3:172468505..172468582,+#_0a51a991cdcb04b9213caaba2b7b72fcp1@ECT2
8.33e-61FFCP PHASE2:Hg19::chr8:124408652..124408712,-#_910322899ee4480b3c49d913830c6d24p1@ATAD2
8.33e-61FFCP PHASE1:Hg19::chr8:124408652..124408712,-#_910322899ee4480b3c49d913830c6d24p1@ATAD2
1.27e-60FFCP PHASE2:Hg19::chr2:29117521..29117569,+#_64f4da3726043135a9c247870059a8e9p1@WDR43
1.27e-60FFCP PHASE1:Hg19::chr2:29117521..29117569,+#_64f4da3726043135a9c247870059a8e9p1@WDR43
1.38e-60FFCP PHASE1:Hg19::chr5:34915805..34915847,+#_87c1e21836fb33ad0392b6676f0e5ea9p1@BRIX1
1.38e-60FFCP PHASE2:Hg19::chr5:34915805..34915847,+#_87c1e21836fb33ad0392b6676f0e5ea9p1@BRIX1
3.64e-60FFCP PHASE2:Hg19::chr12:4647995..4648087,+#_bfa05fff243916f14b76f9b3ebe4964fp1@RAD51AP1
3.64e-60FFCP PHASE1:Hg19::chr12:4647995..4648087,+#_bfa05fff243916f14b76f9b3ebe4964fp1@RAD51AP1
6.38e-60FFCP PHASE2:Hg19::chr5:37288836..37288849,-#_379afc32952c440daedee9ab8a43b0d4p@chr5:37288836..37288849, -
6.38e-60FFCP PHASE1:Hg19::chr5:37288836..37288849,-#_379afc32952c440daedee9ab8a43b0d4p@chr5:37288836..37288849, -
6.59e-60FFCP PHASE1:Hg19::chr18:19192235..19192337,+#_b0537247baae5a8b5d9b8a391b343bc8p1@SNRPD1
6.59e-60FFCP PHASE2:Hg19::chr18:19192235..19192337,+#_b0537247baae5a8b5d9b8a391b343bc8p1@SNRPD1
9.29e-60FFCP PHASE2:Hg19::chr17:38574125..38574168,-#_deefde0b09509b7eb9222d374525591cp1@TOP2A
9.29e-60FFCP PHASE1:Hg19::chr17:38574125..38574168,-#_deefde0b09509b7eb9222d374525591cp1@TOP2A
1.22e-59FFCP PHASE1:Hg19::chr12:118454500..118454585,+#_6594a4e91782575cdec14fc587839521p1@RFC5
1.22e-59FFCP PHASE2:Hg19::chr12:118454500..118454585,+#_6594a4e91782575cdec14fc587839521p1@RFC5
5.0e-59FFCP PHASE2:Hg19::chr1:242011485..242011542,+#_01cd82a4ff04243dd1a58255a3fc0604p1@EXO1
5.0e-59FFCP PHASE1:Hg19::chr1:242011485..242011542,+#_01cd82a4ff04243dd1a58255a3fc0604p1@EXO1
5.74e-59FFCP PHASE2:Hg19::chr10:96363899..96363904,+#_e2ea1dcd51a79f27c5592ae945ba90c6p@chr10:96363899..96363904, +
5.74e-59FFCP PHASE1:Hg19::chr10:96363899..96363904,+#_e2ea1dcd51a79f27c5592ae945ba90c6p@chr10:96363899..96363904, +
6.27e-59FFCP PHASE1:Hg19::chr2:70529150..70529179,-#_b4e146c193198b66bf1584befc644fe0p1@FAM136A
6.27e-59FFCP PHASE2:Hg19::chr2:70529150..70529179,-#_b4e146c193198b66bf1584befc644fe0p1@FAM136A
1.27e-58FFCP PHASE1:Hg19::chr1:68962744..68962772,-#_3e3c00fba71bb0907ec335fc081e8534p1@DEPDC1
1.27e-58FFCP PHASE2:Hg19::chr1:68962744..68962772,-#_3e3c00fba71bb0907ec335fc081e8534p1@DEPDC1
2.97e-58FFCP PHASE1:Hg19::chr17:48450575..48450618,+#_e3cf93f731114198b25cb6604bac8868p1@EME1
2.97e-58FFCP PHASE2:Hg19::chr17:48450575..48450618,+#_e3cf93f731114198b25cb6604bac8868p1@EME1
4.71e-58FFCP PHASE2:Hg19::chr15:69706740..69706754,+#_9a9211969399c3d0b7f056945977d0b2p2@KIF23
4.71e-58FFCP PHASE1:Hg19::chr15:69706740..69706754,+#_9a9211969399c3d0b7f056945977d0b2p2@KIF23
6.8e-58FFCP PHASE2:Hg19::chr8:130951991..130952083,-#_0a23ded3616b8deca1361a340cb522eap1@FAM49B
6.8e-58FFCP PHASE1:Hg19::chr8:130951991..130952083,-#_0a23ded3616b8deca1361a340cb522eap1@FAM49B
8.54e-58FFCP PHASE1:Hg19::chr15:40453204..40453304,+#_a575f01a1ceb5168d47d3cbd330a119cp1@BUB1B
8.54e-58FFCP PHASE2:Hg19::chr15:40453204..40453304,+#_a575f01a1ceb5168d47d3cbd330a119cp1@BUB1B
1.04e-57FFCP PHASE2:Hg19::chr15:91537809..91537824,-#_6934d8d7525ca60f3d6cb0e8c9a53e8bp2@PRC1
1.04e-57FFCP PHASE1:Hg19::chr15:91537809..91537824,-#_6934d8d7525ca60f3d6cb0e8c9a53e8bp2@PRC1
1.18e-57FFCP PHASE2:Hg19::chr4:154265825..154265875,+#_d1b65e826d76fd9ccd9b5af08a5a07b6p1@MND1
1.18e-57FFCP PHASE1:Hg19::chr4:154265825..154265875,+#_d1b65e826d76fd9ccd9b5af08a5a07b6p1@MND1
1.26e-57FFCP PHASE1:Hg19::chr6:20402102..20402152,+#_b206259f5808dace7a5798cbbd7f0cd1p1@E2F3
1.26e-57FFCP PHASE2:Hg19::chr6:20402102..20402152,+#_b206259f5808dace7a5798cbbd7f0cd1p1@E2F3
1.48e-57FFCP PHASE1:Hg19::chr15:89787185..89787263,+#_1cf2c5b6ec92d5789f8f59a692b36176p1@FANCI
1.48e-57FFCP PHASE2:Hg19::chr15:89787185..89787263,+#_1cf2c5b6ec92d5789f8f59a692b36176p1@FANCI
1.5e-57FFCP PHASE1:Hg19::chr15:41625060..41625088,+#_0822cabe7edd262b8dce919eb11b5e89p1@NUSAP1
1.5e-57FFCP PHASE2:Hg19::chr15:41625060..41625088,+#_0822cabe7edd262b8dce919eb11b5e89p1@NUSAP1
3.35e-57FFCP PHASE1:Hg19::chr12:57146095..57146149,-#_37c03af3c00a63bd759dcab4fe369dc3p1@PRIM1
3.35e-57FFCP PHASE2:Hg19::chr12:57146095..57146149,-#_37c03af3c00a63bd759dcab4fe369dc3p1@PRIM1
3.45e-57FFCP PHASE1:Hg19::chr6:35888858..35888887,-#_0f79c51801e2eb66b80670eef562ebd2p1@SRPK1
3.45e-57FFCP PHASE2:Hg19::chr6:35888858..35888887,-#_0f79c51801e2eb66b80670eef562ebd2p1@SRPK1
3.55e-57FFCP PHASE2:Hg19::chr22:22901636..22901715,-#_9c40a5ddf8c0b2df2ec7eb2680c8873fp1@PRAME
3.55e-57FFCP PHASE1:Hg19::chr22:22901636..22901715,-#_9c40a5ddf8c0b2df2ec7eb2680c8873fp1@PRAME
3.96e-57FFCP PHASE1:Hg19::chr12:123237414..123237437,+#_29e038d6133ac3ba74a84690302b07b0p2@DENR
3.96e-57FFCP PHASE2:Hg19::chr12:123237414..123237437,+#_29e038d6133ac3ba74a84690302b07b0p2@DENR
4.25e-57FFCP PHASE1:Hg19::chr2:113522177..113522228,-#_cec2bf50f81af2163d87f1dacfbd1c33p1@CKAP2L
4.25e-57FFCP PHASE2:Hg19::chr2:113522177..113522228,-#_cec2bf50f81af2163d87f1dacfbd1c33p1@CKAP2L
4.48e-57FFCP PHASE2:Hg19::chr5:37371163..37371231,-#_358dfd10b2990d8be595d504e4644e05p1@NUP155
4.48e-57FFCP PHASE1:Hg19::chr5:37371163..37371231,-#_358dfd10b2990d8be595d504e4644e05p1@NUP155
4.86e-57FFCP PHASE1:Hg19::chr10:62538228..62538244,+#_6d0c388dc6d609503ec4421f48c31abcp1@CDK1
4.86e-57FFCP PHASE2:Hg19::chr10:62538228..62538244,+#_6d0c388dc6d609503ec4421f48c31abcp1@CDK1
4.99e-57FFCP PHASE2:Hg19::chr7:152373216..152373260,-#_66204e367bd5fb7178323b6528f597f3p1@XRCC2
4.99e-57FFCP PHASE1:Hg19::chr7:152373216..152373260,-#_66204e367bd5fb7178323b6528f597f3p1@XRCC2

Retrieved from "http://f5-webapp2.gsc.riken.jp/5/sstar/index.php?title=DOID:14566&oldid=3275630"